Heterogenetic antigen-Fc fusion protein capable of inducing antitumor immunity of organism and application thereof

Abstract

The invention discloses a fusion protein with antitumor activity which is protein of 1) or 2) as follows: 1) protein containing the amino acid sequence shown in sequence 2 of the sequence table; 2) protein which is related to antitumor and is derivative of 1) by replacing and / or losing and / or adding one or several amino acid residue in amino acid residue sequence shown in sequence 2 of the sequence table. The vaccine which adopts the fusion protein as active ingredient and GM-CSF and BCG or IFN-gamma and BCG as adjuvant has obvious inhibition for the growth of tumor; in tumor HE staining section, that a great number of inflammatory cells in tumor tissue and around the envelope are infiltrated can be observed so as to prove that effective antitumor immunologic reaction can be induced by combining the adjuvant and the fusion protein.

Description

Technical field

[0001] The invention relates to a heterogeneous antigen-Fc fusion protein which can induce the body's anti-tumor immunity and its application. Background technique

[0002] Breast cancer is one of the most common malignant tumors in women, accounting for 18% of female malignant tumors. Approximately 1.2 million women suffer from breast cancer each year and 500,000 die from breast cancer worldwide. In Western Europe, North America and other developed countries, the incidence of breast cancer is the first among female malignant tumors. Asia is a low-incidence area of ​​breast cancer, but in recent years, the incidence of breast cancer in my country has been increasing year by year, increasing from 17 per 100,000 in 1999 to 52 per 100,000 in 2003. three times. Surgery, chemotherapy and radiotherapy are conventional treatments for breast cancer. With the continuous advancement of the medical level, the treatment technology of primary tumors, especially the surgical t...

Images